Biopharmaceutical CMO Global Market Report 2025

Description

Biopharmaceutical CMO (Contract Manufacturing Organization) is a business that provides manufacturing services, capable of producing small quantities for preclinical research and development, as well as larger quantities required for clinical trials and commercialization. Biopharmaceutical CMOs play a crucial role in reducing overall operational risk and time to market for pharmaceutical products.

The main types of biopharmaceutical CMO products include biologics and biosimilars. Biologics encompass a diverse range of products derived from human, animal, or microbial sources, serving as medications. These substances are produced from living organisms or contain components thereof. Examples of biologic medications include vaccines, blood products, cells, allergens, genes, tissues, and recombinant proteins. Biopharmaceutical CMO products can be sourced from various origins, including mammalian and non-mammalian sources. Biopharmaceutical CMO services cover a spectrum of activities such as manufacturing, fill and finish operations, analytical and quality control studies, and packaging. These services are crucial for pharmaceutical companies looking to outsource certain aspects of their production processes, allowing them to focus on research, development, and commercialization efforts.

The biopharmaceutical CMO market research report is one of a series of new reports from The Business Research Company that provides biopharmaceutical CMO market statistics, including biopharmaceutical CMO industry global market size, regional shares, competitors with a biopharmaceutical CMO market share, detailed biopharmaceutical CMO market segments, market trends and opportunities, and any further data you may need to thrive in the biopharmaceutical CMO industry. This biopharmaceutical CMO market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The biopharmaceutical CMO market size has grown rapidly in recent years. It will grow from $24.81 billion in 2024 to $28.09 billion in 2025 at a compound annual growth rate (CAGR) of 13.2%. The growth in the historic period can be attributed to increasing demand for biopharmaceuticals, globalization, rise in healthcare expenditure, regulatory support, increased research funding.

The biopharmaceutical CMO market size is expected to see rapid growth in the next few years. It will grow to $48.04 billion in 2029 at a compound annual growth rate (CAGR) of 14.4%. The growth in the forecast period can be attributed to rise in telehealth and remote trials, global health initiatives, rise in disposable income, global health initiatives. Major trends in the forecast period include advanced therapies dominance, digitalization and industry 4.0, continuous manufacturing, sustainability and green practices.

An increase in the strength of venture capital investments in the life science sector is expected to fuel the growth of the biopharmaceutical Contract Manufacturing Organization (CMO) market. The life sciences sector includes businesses and organizations involved in research and development related to living organisms. The strength of venture capital investments indicates how effectively a model, test, or system can operate when parameters or assumptions are changed. For example, in May 2024, the Department of Health and Social Care, a UK-based government agency, reported that the core biopharmaceutical sector generated £46.7 billion ($59.32 billion) in revenue in 2021/22, representing 43% of the entire life sciences industry. Additionally, in 2024, AusBiotech, an organization based in Australia, stated that the biotechnology sector reached USD 5.66 billion (AU$8.67 billion) in total revenues by 2021, with a growth rate of 4.4%. This significant investment is anticipated to boost the manufacturing of biopharmaceuticals, contributing to the growth of the biopharmaceutical CMO market.

The increasing burden of chronic diseases is poised to fuel the growth of the biopharmaceutical CMO market. Chronic diseases, characterized by prolonged health conditions requiring ongoing medical management, represent a significant global health challenge. Biopharmaceutical CMOs play a crucial role in addressing chronic diseases by expediting drug development, ensuring cost-effective production, and maintaining high-quality standards. According to the National Library of Medicine, the US population aged 50 and older is projected to increase by 61.11% from 137.25 million in 2020 to 221.13 million in 2050, with the number of individuals with at least one chronic disease estimated to rise by 99.5% from 71.522 million in 2020 to 142.66 million by 2050. This growing burden of chronic diseases is a key driver for the biopharmaceutical CMO market.

Technological advancement emerges as a prominent trend in the biopharmaceutical CMO market. Major companies in this sector are focusing on advancing technologies through research and development, leveraging the Internet of Things (IoT). The IoT involves the application of networked sensors and actuators for monitoring and controlling manufacturing environments. The vast amount of data generated by IoT-enabled systems can be analyzed to enhance production efficiency, automate tasks, and enable adaptable manufacturing. In February 2022, M2Cloud and Thales collaborated to develop an IoT-based LTE monitoring system for biopharmaceutical monitoring. This system facilitates real-time monitoring of freezers, refrigerated warehouses, and delivery boxes, ensuring temperature and position information verification. Technological advancements like these contribute to the safety and efficiency of biopharmaceutical product management, driving growth in the biopharmaceutical CMO market.

Leading companies in the biopharmaceutical CMO market are increasingly pursuing strategic partnerships to create innovative biopharmaceutical products. These collaborations enable biopharmaceutical CMO firms to pool resources and expertise, enhance research and development capabilities, broaden their market presence, and speed up commercialization. This approach ultimately fosters innovation and growth within the biopharmaceutical CMO sector. For example, in May 2024, BioConnection, a contract manufacturing company based in the Netherlands, joined forces with AGC Biologics, a contract development and manufacturing organization in the United States. Through this partnership, they aim to provide a streamlined, all-encompassing solution for biopharmaceutical development and manufacturing, thereby expediting timelines and simplifying processes for drug developers.

In May 2023, WACKER, a chemical company based in Germany, acquired ADL BioPharma for an undisclosed amount. This acquisition aims to strengthen WACKER's biotechnology operations and expand its fermentation capacities for sustainably produced food ingredients, aligning with its future growth goals. ADL BioPharma is a contract manufacturing company located in Spain that specializes in the development and production of high-quality fermentation products.

Major companies operating in the biopharmaceutical cmo market include Lonza Group AG, Fujifilm Diosynth Biotechnologies USA Inc., Thermo Fisher Scientific Inc., Samsung Biologics, WuXi AppTec, Catalent, Inc., Rentschler Biopharma SE, Boehringer Ingelheim, Recipharm AB, AGC Biologics, CMC Biologics, KBI Biopharma, Vetter Pharma International GmbH, Emergent BioSolutions Inc., Aenova Group, Synlogic, Inc., MedImmune (AstraZeneca), BioLife Sciences, Bio-Xcellence (Boehringer Ingelheim), AbbVie Contract Manufacturing, PCI Pharma Services, AltheaDx, Daxor Corporation, Genomatica, Inc., Astellas Pharma, Juno Therapeutics (Celgene), Medpace, Celerion, Evonik Industries AG

North America was the largest region in the biopharmaceutical CMO market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the biopharmaceutical CMO market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.

The countries covered in the biopharmaceutical CMO market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK and USA.

The biopharmaceutical CMO market includes revenues earned by entities by process development. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Biopharmaceutical CMO Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on biopharmaceutical cmo market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for biopharmaceutical cmo ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The biopharmaceutical cmo market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:1) By Product: Biologics; Biosimilars
2) By Source: Mammalian; Non-Mammalian
3) By Service: Manufacturing; Fill And Finish Operations; Analytical And QC Studies; Packaging
Subsegments:
1) By Biologics: Monoclonal Antibodies; Recombinant Proteins; Vaccines; Cell and Gene Therapies
2) By Biosimilars: Biosimilar Monoclonal Antibodies; Biosimilar Recombinant Proteins; Biosimilar Insulins; Biosimilar Growth Hormones
Companies Mentioned: Lonza Group AG; Fujifilm Diosynth Biotechnologies USA Inc.; Thermo Fisher Scientific Inc.; Samsung Biologics; WuXi AppTec
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery format: PDF, Word and Excel Data Dashboard.

Product Code: r21150

1. Executive Summary

2. Biopharmaceutical CMO Market Characteristics

3. Biopharmaceutical CMO Market Trends And Strategies

4. Biopharmaceutical CMO Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Biopharmaceutical CMO Growth Analysis And Strategic Analysis Framework

5.1. Global Biopharmaceutical CMO PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Biopharmaceutical CMO Market Growth Rate Analysis
5.4. Global Biopharmaceutical CMO Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Biopharmaceutical CMO Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Biopharmaceutical CMO Total Addressable Market (TAM)

6. Biopharmaceutical CMO Market Segmentation

6.1. Global Biopharmaceutical CMO Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Biologics
Biosimilars
6.2. Global Biopharmaceutical CMO Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Mammalian
Non-Mammalian
6.3. Global Biopharmaceutical CMO Market, Segmentation By Service, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Manufacturing
Fill And Finish Operations
Analytical And QC Studies
Packaging
6.4. Global Biopharmaceutical CMO Market, Sub-Segmentation Of Biologics, By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Monoclonal Antibodies
Recombinant Proteins
Vaccines
Cell and Gene Therapies
6.5. Global Biopharmaceutical CMO Market, Sub-Segmentation Of Biosimilars, By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Biosimilar Monoclonal Antibodies
Biosimilar Recombinant Proteins
Biosimilar Insulins
Biosimilar Growth Hormones

7. Biopharmaceutical CMO Market Regional And Country Analysis

7.1. Global Biopharmaceutical CMO Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Biopharmaceutical CMO Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Biopharmaceutical CMO Market

8.1. Asia-Pacific Biopharmaceutical CMO Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Biopharmaceutical CMO Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Biopharmaceutical CMO Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Biopharmaceutical CMO Market, Segmentation By Service, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Biopharmaceutical CMO Market

9.1. China Biopharmaceutical CMO Market Overview
9.2. China Biopharmaceutical CMO Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Biopharmaceutical CMO Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Biopharmaceutical CMO Market, Segmentation By Service, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Biopharmaceutical CMO Market

10.1. India Biopharmaceutical CMO Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Biopharmaceutical CMO Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Biopharmaceutical CMO Market, Segmentation By Service, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Biopharmaceutical CMO Market

11.1. Japan Biopharmaceutical CMO Market Overview
11.2. Japan Biopharmaceutical CMO Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Biopharmaceutical CMO Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Biopharmaceutical CMO Market, Segmentation By Service, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Biopharmaceutical CMO Market

12.1. Australia Biopharmaceutical CMO Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Biopharmaceutical CMO Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Biopharmaceutical CMO Market, Segmentation By Service, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Biopharmaceutical CMO Market

13.1. Indonesia Biopharmaceutical CMO Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Biopharmaceutical CMO Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Biopharmaceutical CMO Market, Segmentation By Service, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Biopharmaceutical CMO Market

14.1. South Korea Biopharmaceutical CMO Market Overview
14.2. South Korea Biopharmaceutical CMO Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Biopharmaceutical CMO Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Biopharmaceutical CMO Market, Segmentation By Service, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Biopharmaceutical CMO Market

15.1. Western Europe Biopharmaceutical CMO Market Overview
15.2. Western Europe Biopharmaceutical CMO Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Biopharmaceutical CMO Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Biopharmaceutical CMO Market, Segmentation By Service, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Biopharmaceutical CMO Market

16.1. UK Biopharmaceutical CMO Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Biopharmaceutical CMO Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Biopharmaceutical CMO Market, Segmentation By Service, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Biopharmaceutical CMO Market

17.1. Germany Biopharmaceutical CMO Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Biopharmaceutical CMO Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Biopharmaceutical CMO Market, Segmentation By Service, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Biopharmaceutical CMO Market

18.1. France Biopharmaceutical CMO Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Biopharmaceutical CMO Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Biopharmaceutical CMO Market, Segmentation By Service, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Biopharmaceutical CMO Market

19.1. Italy Biopharmaceutical CMO Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy Biopharmaceutical CMO Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy Biopharmaceutical CMO Market, Segmentation By Service, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Biopharmaceutical CMO Market

20.1. Spain Biopharmaceutical CMO Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Biopharmaceutical CMO Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Biopharmaceutical CMO Market, Segmentation By Service, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Biopharmaceutical CMO Market

21.1. Eastern Europe Biopharmaceutical CMO Market Overview
21.2. Eastern Europe Biopharmaceutical CMO Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Biopharmaceutical CMO Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Biopharmaceutical CMO Market, Segmentation By Service, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Biopharmaceutical CMO Market

22.1. Russia Biopharmaceutical CMO Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Biopharmaceutical CMO Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Biopharmaceutical CMO Market, Segmentation By Service, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Biopharmaceutical CMO Market

23.1. North America Biopharmaceutical CMO Market Overview
23.2. North America Biopharmaceutical CMO Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Biopharmaceutical CMO Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Biopharmaceutical CMO Market, Segmentation By Service, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Biopharmaceutical CMO Market

24.1. USA Biopharmaceutical CMO Market Overview
24.2. USA Biopharmaceutical CMO Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Biopharmaceutical CMO Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Biopharmaceutical CMO Market, Segmentation By Service, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Biopharmaceutical CMO Market

25.1. Canada Biopharmaceutical CMO Market Overview
25.2. Canada Biopharmaceutical CMO Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Biopharmaceutical CMO Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Biopharmaceutical CMO Market, Segmentation By Service, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Biopharmaceutical CMO Market

26.1. South America Biopharmaceutical CMO Market Overview
26.2. South America Biopharmaceutical CMO Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Biopharmaceutical CMO Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Biopharmaceutical CMO Market, Segmentation By Service, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Biopharmaceutical CMO Market

27.1. Brazil Biopharmaceutical CMO Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Biopharmaceutical CMO Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Biopharmaceutical CMO Market, Segmentation By Service, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Biopharmaceutical CMO Market

28.1. Middle East Biopharmaceutical CMO Market Overview
28.2. Middle East Biopharmaceutical CMO Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Biopharmaceutical CMO Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Biopharmaceutical CMO Market, Segmentation By Service, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Biopharmaceutical CMO Market

29.1. Africa Biopharmaceutical CMO Market Overview
29.2. Africa Biopharmaceutical CMO Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Biopharmaceutical CMO Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Biopharmaceutical CMO Market, Segmentation By Service, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Biopharmaceutical CMO Market Competitive Landscape And Company Profiles

30.1. Biopharmaceutical CMO Market Competitive Landscape
30.2. Biopharmaceutical CMO Market Company Profiles
- 30.2.1. Lonza Group AG Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. Fujifilm Diosynth Biotechnologies USA Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. Thermo Fisher Scientific Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. Samsung Biologics Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. WuXi AppTec Overview, Products and Services, Strategy and Financial Analysis

31. Biopharmaceutical CMO Market Other Major And Innovative Companies

31.1. Catalent, Inc.
31.2. Rentschler Biopharma SE
31.3. Boehringer Ingelheim
31.4. Recipharm AB
31.5. AGC Biologics
31.6. CMC Biologics
31.7. KBI Biopharma
31.8. Vetter Pharma International GmbH
31.9. Emergent BioSolutions Inc.
31.10. Aenova Group
31.11. Synlogic, Inc.
31.12. MedImmune (AstraZeneca)
31.13. BioLife Sciences
31.14. Bio-Xcellence (Boehringer Ingelheim)
31.15. AbbVie Contract Manufacturing

32. Global Biopharmaceutical CMO Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Biopharmaceutical CMO Market

34. Recent Developments In The Biopharmaceutical CMO Market

35. Biopharmaceutical CMO Market High Potential Countries, Segments and Strategies

35.1 Biopharmaceutical CMO Market In 2029 - Countries Offering Most New Opportunities
35.2 Biopharmaceutical CMO Market In 2029 - Segments Offering Most New Opportunities
35.3 Biopharmaceutical CMO Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations
36.2. Currencies
36.3. Historic And Forecast Inflation Rates
36.4. Research Inquiries
36.5. The Business Research Company
36.6. Copyright And Disclaimer